The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Oil prices recovered from two-month lows, with both Brent crude futures and WTI futures rising as attacks on shipping in and around the Strait of Hormuz kept supply concerns alive.
November brings several closely watched FDA decisions, with Regeneron and its partner Alnylam’s therapy for generalized myasthenia gravis and Roche’s Gazyva for primary membranous nephropathy in the spotlight this week.